A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
← catalyst calendarNCT07205159 · readout in 203 d
Sponsored by Forte Biosciences, Inc. (industry) · FBRX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
32estimated
Sites
6
Countries
Australia, New Zealand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-10-23 | actual | When the study began enrolling |
| Primary completion | 2027-03-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-10 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alopecia Areata
Interventions
- Drug: FB102
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
measured Upto 36 Weeks post first dose administration
Change from Baseline of Severity of Alopecia Tool (SALT) score at Week 16.
measured From Screening through Week 16.
Permalink · FBRX's whole pipeline · Catalyst calendar · Every registered study · What changed